Sangamo Therapeutics Signs an Option Agreement with Brammer Bio for its AAV Manufacturing Facility

Shots:

• Sangamo has an option to access Brammer’s AAV manufacturing facility with 2000-L bioreactor scale used in development of gene therapies. Additionally, Sangamo has rights for Brammer’s viral vector manufacturing facility to utilize it in combination with its California facility to expand its early stage products to late stage
• The focus of the agreement is to develop AVV-based genomic in-vivo & ex-vivo therapies and genome editing candidates including ST-920 for Fabry Disease utilizing Brammer’s manufacturing facilities
• ST-920 is a gene therapy candidate with AAV vector carrying a GLA gene enabling the liver to produce α-Gal A enzyme and will be evaluated in P-I/II for Fabry disease in 2019. In 2020, Sangamo plans to build cGMP manufacturing facilit in Brisbane, California, for P-I/II trials of products

Click here to read full press release/ article | Ref: Sangamo Therapeutics | Image: Twitter